Erbitux diagnostic latest adjunct to cancer therapy.
Mitchell
Peter
P
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015415:Biomarkers; D014408:Biomarkers, Tumor; D001709:Biotechnology / Q000379:methods; D000068818:Cetuximab; D017024:Chemotherapy, Adjuvant; D015179:Colorectal Neoplasms / Q000175:diagnosis* / Q000188:drug therapy; D066246:ErbB Receptors / Q000378:metabolism; D006801:Humans; D008024:Ligands; D012680:Sensitivity and Specificity
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015415:Biomarkers; D014408:Biomarkers, Tumor; D008024:Ligands; D066246:ErbB Receptors; D000068818:Cetuximab